Avidity Biosciences, Inc. RNA
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$308 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$267 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$249 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$235 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$203 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.88MShares$199 Million4.75% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.3MShares$182 Million4.04% of portfolio
-
Janus Henderson Group PLC London, X04.9MShares$142 Million0.12% of portfolio
-
State Street Corp Boston, MA4.71MShares$136 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.08MShares$89.1 Million0.26% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+20.38%
|
-
|
|
Jan 06
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+18.82%
|
-
|
|
Jan 06
2025
|
Sarah Boyce President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
82,500
+19.17%
|
-
|
|
Jan 06
2025
|
Michael F Mac Lean Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+18.81%
|
-
|
|
Jan 06
2025
|
John B Moriarty Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Jan 06
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+22.45%
|
-
|
|
Jan 06
2025
|
Eric Mosbrooker Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+29.03%
|
-
|
|
Jan 06
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+29.42%
|
-
|
|
Jan 06
2025
|
Charles Calderaro Iii Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Dec 18
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
11,151
-11.86%
|
$356,832
$32.66 P/Share
|
|
Dec 18
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
31,855
-10.72%
|
$1,019,360
$32.66 P/Share
|
|
Dec 18
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,151
-11.85%
|
$356,832
$32.66 P/Share
|
|
Dec 18
2024
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,742
-14.92%
|
$407,744
$32.66 P/Share
|
|
Dec 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-21.01%
|
$825,000
$33.26 P/Share
|
|
Dec 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+17.36%
|
$350,000
$14.22 P/Share
|
|
Dec 11
2024
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
24,000
-21.94%
|
$840,000
$35.77 P/Share
|
|
Dec 11
2024
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+17.99%
|
$528,000
$22.47 P/Share
|
|
Nov 19
2024
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
3,323
-18.31%
|
$139,566
$42.12 P/Share
|
|
Nov 19
2024
|
Arthur A Levin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,323
+15.47%
|
$3,323
$1.24 P/Share
|
|
Nov 18
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-21.01%
|
$1,025,000
$41.14 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 994K shares |
|---|---|
| Exercise of conversion of derivative security | 1.32M shares |
| Bona fide gift | 22.5K shares |
| Open market or private sale | 1.71M shares |
|---|---|
| Bona fide gift | 22.5K shares |